Reata Pharmaceuticals

Reata CEO Warren Huff

Biogen To Acquire Plano-Based Biotech Reata Pharmaceuticals

by | Jul 28, 2023
Founded in 2002, rare disease drugmaker Reata has made significant advances in therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. The company's FDA-approved SKYCLARYS is the first and only approved treatment in the U.S. for Friedreich’s ataxia, a genetic nervous system disorder.
Plano’s Reata Pharmaceuticals Appoints EVP/Chief R&D Officer
by | Jun 16, 2023
In a pivotal year, which saw Reata Pharmaceuticals halt research for a kidney disease treatment and receive FDA approval for its first-to-market degenerative disease treatment, the company welcomes Dr. Rajiv Patni as Chief R&D Officer. Patni marks this as an "inflection point to become a global, commercial-stage company with an expanding pipeline in both rare and common serious diseases."
JLL Office Insight: Dallas Still Outperforms the Rest of the Nation
by | Apr 13, 2023
Here are JLL's findings in its last Office Insight report. Plus, JLL Dallas Managing Directors Cribb Altman and Blake Shipley share their expert opinions on everything from tenant behavior to the emergence of a new class of investors in the market.
On Rare Disease Day, Plano Biotech Reata Pharmaceuticals Gets Its First FDA Approval
by | Mar 2, 2023
The FDA approval is not only a first for Reata's treatment of ultra-rare disease Friedreich's Ataxia. It's a first in the company's history, reports FiercePharma. On the news, Reata’s stock skyrocketed nearly 200% Wednesday, according to the Dallas Morning News, which cited an estimate that the drug will create a revenue stream in excess of $1 billion.